Corcept Therapeutics

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

Retrieved on: 
Wednesday, December 15, 2021
Transfer, Board of directors, Tender offer, Mini-tender offer, Food, CORT, Board, Exercise, NASDAQ, Lists of diseases, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, GLOBE, Tender, Pharmaceutical industry, Security (finance), Corcept Therapeutics

The Tender Offer is subject to other terms and conditions, which are described in detail in the offer to purchase.

Key Points: 
  • The Tender Offer is subject to other terms and conditions, which are described in detail in the offer to purchase.
  • Except for the waiver of the share price condition set forth above, the terms and conditions of the Tender Offer remain the same.
  • The sole dealer manager for the Tender Offer is Truist Securities, Inc. D.F.
  • King is serving as the information agent for the Tender Offer and Continental Stock Transfer & Trust Company is serving as the depositary.

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, December 15, 2021
Legal, Professional Services, U.S. Securities and Exchange Commission, Jeanne Eagels, Company, Accountability Act, CORT, Health Insurance Portability and Accountability Act, Sale, Telephone, NASDAQ, P.C, District, Record, News, HIPAA, Online gambling, Corcept Therapeutics

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) on behalf of Corcept stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) on behalf of Corcept stockholders.
  • Our investigation concerns whether Corcept has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Corcept further disclosed that [t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

Corcept Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Thursday, December 9, 2021
CORT, District, Corcept Therapeutics, Record, NASDAQ, GLOBE, Review, Sale, Therapy

LOS ANGELES, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • Corcept Therapeutics slumps as much as 28% to the lowest in over a year after saying in a filing that on Nov. 15 it received a records subpoena from the U.S.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Federation Bio Expands Leadership Team To Support Continued Advancement of Engineered Bacterial Cell Therapies

Retrieved on: 
Tuesday, November 30, 2021
Genentech, Corcept Therapeutics, Royal Postgraduate Medical School, Federation, Industry, Nephrology, Endocrinology, University of California, San Francisco, Hammersmith Hospital, Inflammation, Amgen, SAN, University, Lists of diseases, Therapy, Genetic engineering, School, Law, University Hospital Heidelberg, Roche, Biotechnology, FDA, Bio, Pharmaceutical industry, Medicine

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.
  • Andreas Grauer, M.D., and Jessie Richardson, J.D., Ph.D.,have joined Federation Bio as chief medical officer and general counsel, respectively.
  • "Andreas and Jessie are both recognized industry leaders whose collective expertise perfectly complements that of our existing leadership team," said Emily Drabant Conley, Ph.D., chief executive officer at Federation Bio.
  • Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies.

Corcept Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 10, 2021
NASDAQ, Food, Lists of diseases, Patient, Corcept Therapeutics, CORT, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced that the company will present at the following investor conferences:

Key Points: 
  • MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced that the company will present at the following investor conferences:
    Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol.
  • Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushings syndrome.
  • Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol.
  • The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Wednesday, October 27, 2021
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, NASDAQ, GLOBE, Corcept Therapeutics, Food, Lists of diseases, CORT, Pharmaceutical industry

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2021.

Key Points: 
  • MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2021.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call.
  • Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol.

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, September 8, 2021

If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993.

Key Points: 
  • If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993.
  • Morris Kandinov is investigating Odonate regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Corcept regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Thursday, July 22, 2021
Corcept Therapeutics, NASDAQ, Cort, Finance, Financial markets, Economy of the United States

MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021.

Key Points: 
  • MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call.
  • Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol.

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Life sciences, Gilead Sciences, Pharmaceutical industry, Corcept Therapeutics

Im very pleased to welcome Amy to our executive team, said Joseph K. Belanoff, MD, Corcepts Chief Executive Officer.

Key Points: 
  • Im very pleased to welcome Amy to our executive team, said Joseph K. Belanoff, MD, Corcepts Chief Executive Officer.
  • She played a key role in building the talented teams that enabled Gilead Sciences great success.
  • Flood has nearly 25 yearsof experience in team development and communications in the biotech industry.
  • Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol.

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

Retrieved on: 
Thursday, June 10, 2021
Corcept Therapeutics, Anxiety, Glucocorticoids, Cortisol, Cort, Health care

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the companys Board of Directors.

Key Points: 
  • MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the companys Board of Directors.
  • Mr. Murray is currently Senior Vice President, Finance, Strategy and Investor Relations at Orca Bio, a privately held biotechnology company developing allogeneic cell therapies in blood, immune, and genetic diseases.
  • I am very pleased to welcome Josh to our board, said Joseph K. Belanoff, MD, Corcepts Chief Executive Officer.
  • Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol.